Trial · NCT04770779
Results by group77
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 77
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) | Mitapivat | 30.4 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) | Placebo | 12.6 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved TRR2 | Mitapivat | 13.5 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved TRR2 | Placebo | 2.3 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved TRR3 | Mitapivat | 14.6 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved TRR3 | Placebo | 1.1 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved TRR4 | Mitapivat | 7.6 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved TRR4 | Placebo | 1.1 | percentage of participants | ||
| Double-blind Period: Percent Change From Baseline in Transfused RBC Units | Mitapivat | 10.96 | Standard Error 2.149 | percent change | |
| Double-blind Period: Percent Change From Baseline in Transfused RBC Units | Placebo | 3.32 | Standard Error 2.846 | percent change | |
| Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence | Mitapivat | 9.9 | percentage of participants | ||
| Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence | Placebo | 1.1 | percentage of participants | ||
| Double-blind Period: Change From Baseline in Iron Levels | Mitapivat | -4.57 | Standard Error 0.949 | micromoles per liter (µmol/L) | |
| Double-blind Period: Change From Baseline in Iron Levels | Placebo | 2.06 | Standard Error 1.280 | micromoles per liter (µmol/L) | |
| Double-blind Period: Change From Baseline in Serum Ferritin Levels | Mitapivat | 45.3 | Standard Error 88.90 | micrograms per liter (µg/L) | |
| Double-blind Period: Change From Baseline in Serum Ferritin Levels | Placebo | 76.3 | Standard Error 119.84 | micrograms per liter (µg/L) | |
| Double-blind Period: Change From Baseline in Total Iron Binding Capacity | Mitapivat | -21.80 | Standard Error 3.597 | µmol/L | |
| Double-blind Period: Change From Baseline in Total Iron Binding Capacity | Placebo | -1.23 | Standard Error 5.053 | µmol/L | |
| Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels | Mitapivat | 0.079 | Standard Error 0.0261 | Ratio | |
| Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels | Placebo | -0.013 | Standard Error 0.0371 | Ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04770779/results